Skip to main content

Table 2 Population pharmacokinetic parameters of terlipressin and L-VP in patients with HRS (final PK model)

From: Pharmacokinetic and pharmacodynamic analyses of terlipressin in patients with hepatorenal syndrome

Parameters Estimate (RSE%)a 95% CIb
CLA (L/h) 27.4 (8.7) 24.8–31.1
WT on CLAc 0.549 (36.2) 0.413–0.850
V1A (L) 6.31 (23.3) 4.87–9.33
QAd (L/h) 35.6 (16.7) 24.0–43.1
V2Ad (L) 18.4 (8.6) 15.6–22.1
CLM/Fm (L/h) 318 (11.5) 283–363
VM/Fm (L) 1370 (18.8) 1190–1520
BSV of CLA (CV%) 34.8 (39.4) 24.7–50.3
BSV of V1A (CV%) 61.9 (121.9) 35.5–113.1
BSV of CLM/Fm (CV%) 65.8 (33.5) 54.2–73.1
BSV of VM/Fm (CV%) 67.7 (34.9) 53.3–81.9
Residual errors (CV%)
Terlipressin—study 1 70.0 (14.1) 59.5–76.2
L-VP—study 1 47.2 (5.6) 37.1–59.4
Terlipressin—study 2 39.7 (6.5) 28.2–51.6
L-VP—study 2 26.9 (18.4) 20.9–30.3
  1. BSV, between-subject variability; CI, confidence interval; CLA, clearance of terlipressin; CLM/Fm, apparent clearance for L-VP; CV%, coefficient of variation; HRS, hepatorenal syndrome; L-VP, lysine-vasopressin PK, pharmacokinetic; QA, intercompartmental flow; RSE, relative standard error; V1A and V2A, volume of central compartment and peripheral compartment for terlipressin, respectively; VM/Fm, apparent volume of L-VP; WT, body weight
  2. aParameter precision (RSE%) is expressed as CV%
  3. b95% CI estimated from bootstrap of 1110 replicated samples
  4. cCLA = 27.4 * (WT/86)0.549
  5. dBSV was fixed as 0